Bowhead Specialty (NYSE:BOW) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Bowhead Specialty (NYSE:BOW) posted its earnings results on Tuesday. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.02, FiscalAI reports. The company had revenue of $151.68 million for the quarter, compared to the consensus estimate of $145.99 million. Bowhead Specialty had a return on equity of 13.53% and a net margin of 10.12%.

Here are the key takeaways from Bowhead Specialty’s conference call:

• Bowhead grew gross written premium ~24% for 2025 (Q4 +21%), led by Casualty (full-year +28%) and accelerating digital business Baleen (>$21M in 2025), with construction project wins adding roughly 30% to Q4 Casualty premiums.
• The company reduced its expense ratio to 29.8% through scaling and technology initiatives, helping drive a ~30% increase in adjusted net income and an adjusted return on equity of 13.6%.
• The full-year loss ratio increased to 66.7% (up 2.3 points) and the current accident?year loss ratio rose 1.8 points; management emphasizes conservative reserving and prior?year reallocations, but limited long?tail experience leaves reserve uncertainty.
• For 2026 Bowhead guides ~20% GWP growth, a combined ratio in the mid?to?high 90s and mid?teens ROE, while increasing cyber quota share to 65% and issuing $150M of 7.75% senior notes to support regulatory capital — actions that balance growth with added reinsurance and leverage.

Bowhead Specialty Stock Performance

Shares of BOW opened at $24.20 on Wednesday. The firm has a market cap of $793.11 million, a PE ratio of 15.51, a PEG ratio of 0.81 and a beta of -1.05. The firm’s 50 day moving average price is $25.83 and its 200 day moving average price is $26.99. Bowhead Specialty has a twelve month low of $22.15 and a twelve month high of $42.29.

Key Bowhead Specialty News

Here are the key news stories impacting Bowhead Specialty this week:

• Positive Sentiment: Q4 results beat estimates — EPS $0.47 and revenue $151.68M, topping consensus; net income reported at $14.8M. These beats support upward re-rating on near-term profitability. Business Wire Release
• Positive Sentiment: Gross written premiums (GWP) rose ~21.3% to $224.1M in Q4 — strong top-line growth in core lines that supports margin leverage as underwriting scales. Reinsurance News
• Positive Sentiment: Management guidance/plan: expects ~20% premium growth in 2026 driven by accelerating digital underwriting and distribution—this is forward-looking growth that investors typically reward. MSN Article
• Neutral Sentiment: Analyst/coverage notes: multiple outlets (Zacks, MarketBeat) highlight the beat but point to modest EPS upside and valuation metrics (P/E ~15.5). These analyses may temper enthusiasm for longer-term upside until guidance is realized. Zacks Coverage
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper due diligence (slide deck, call transcript, and summaries). Investors should review comments on loss ratios, reinsurance, and capital deployment for downside/risk context. Earnings Call Transcript

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BOW. Piper Sandler raised their price target on Bowhead Specialty from $30.00 to $32.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. Morgan Stanley reduced their price objective on Bowhead Specialty from $31.00 to $29.00 and set an “equal weight” rating on the stock in a research report on Monday, November 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bowhead Specialty in a report on Monday, December 29th. Zacks Research downgraded shares of Bowhead Specialty from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Finally, Royal Bank Of Canada started coverage on shares of Bowhead Specialty in a research report on Monday, November 24th. They set an “outperform” rating and a $33.00 target price on the stock. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bowhead Specialty has a consensus rating of “Hold” and a consensus price target of $33.83.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Bowhead Specialty in the 2nd quarter valued at $52,000. Royal Bank of Canada grew its stake in Bowhead Specialty by 45.5% in the fourth quarter. Royal Bank of Canada now owns 2,065 shares of the company’s stock valued at $59,000 after acquiring an additional 646 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Bowhead Specialty by 99.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,926 shares of the company’s stock worth $72,000 after acquiring an additional 958 shares in the last quarter. Quarry LP grew its holdings in shares of Bowhead Specialty by 19,489.5% during the third quarter. Quarry LP now owns 3,722 shares of the company’s stock worth $101,000 after buying an additional 3,703 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its stake in Bowhead Specialty by 2,227.8% in the 4th quarter. Quadrant Capital Group LLC now owns 3,771 shares of the company’s stock valued at $108,000 after buying an additional 3,609 shares during the last quarter.

Bowhead Specialty Company Profile

Bowhead Specialty Holdings Inc provides specialty property and casualty insurance products in the United States. It underwrites casualty insurance solutions for risks in the construction, distribution, heavy manufacturing, real estate, and hospitality segments; professional liability insurance solutions for financial institutions, private and public directors and officers liability insurance, errors and omissions liability insurance, and cyber segments; and healthcare solutions for hospitals, senior care providers, managed care organizations, miscellaneous medical facilities, and healthcare management liability segments.